China's Fermentation Giants Are Pivoting to Mycoprotein as Pharma Profits Thin
- Gauri Khanna
- Aug 12
- 3 min read
A new report by the Good Food Institute APAC finds that China's largest fermentation manufacturers are redirecting capacity toward mycoprotein, yeast proteins, and precision-fermented fats as pharmaceutical margins shrink.
Decades of investment in fermentation-based pharmaceuticals and vitamins have left China with extensive production infrastructure, technical expertise, and low operating costs that can now be redeployed toward alternative proteins.
The shift, backed by state policy and new facility investment, could reshape the global economics of alternative protein production and create both opportunities and risks for international companies considering Chinese partnerships.
China's fermentation industry has spent decades quietly supplying the world with pharmaceuticals, amino acids, and vitamins. Now, according to a report published by the Good Food Institute (GFI) APAC, its largest manufacturers are beginning to turn that accumulated capacity toward a different end: mycoprotein and other alternative proteins. The report, authored by Australian biotech and geopolitics researcher Dr. Dirk van der Kley, examines how a combination of shrinking pharmaceutical margins and coordinated government support is nudging China's fermentation giants toward novel food production, with potentially significant consequences for the global alternative protein industry.
Why Pharma Margins Are Driving the Shift
The logic behind the pivot is largely economic. Chinese fermentation companies have historically concentrated on pharmaceuticals because the sector offers high prices for relatively small volumes. That arithmetic is changing. As biopharmaceutical capacity has expanded and competition from biosimilars, which are lower-cost copies of biological medicines, has intensified, returns on some pharmaceutical manufacturing have narrowed. Companies with idle or underutilised fermentation infrastructure are now evaluating food applications, particularly those that can command a premium price.
Commodity amino acid and vitamin producers face comparable pressure. According to the GFI APAC report, prices paid in Europe for amino acids such as L-lysine sulfate and L-threonine fell sharply between January 2022 and November 2025, and some vitamin producers slowed or halted output in response to oversupply. The scale of China's position in these markets is considerable: as of 2024, the country accounted for roughly half of global amino acid exports and 38 percent of vitamin exports. When margins compress across that volume, the incentive to find higher-value applications for existing fermentation capacity becomes significant.
State Policy and New Facilities
The commercial pressure aligns with government intent. Alternative proteins have been incorporated into China's "new quality productive forces" strategy, a policy framework for upgrading the country's industrial and technological base. Preparatory documents for China's forthcoming biomanufacturing Five-Year Plan reference synthetic biology, microbial protein, and new food sources explicitly. In August 2025, the government published a list of 36 target biomanufactured products, three of which relate directly to alternative proteins.
Physical investment is already under way. Fushine Biotech, based in Jingdezhen, is expanding an existing 1,200-tonne mycoprotein production line. Startup More Meat is building a 20,000-tonne mycoprotein facility in Guangzhou through a joint venture. For context, Marlow Ingredients in the United Kingdom, the producer behind Quorn, operates what is currently the world's largest mycoprotein facility, with annual capacity exceeding 67,000 tonnes. China's emerging capacity is not yet at that scale, but the trajectory and the policy backing suggest ambitions that extend well beyond domestic supply.
Implications and Risks for International Companies
The GFI APAC report frames China's fermentation pivot as a potential opening for international alternative protein startups. Chinese partners could offer access to lower production costs and faster scale-up than most Western markets can currently provide. The economics are difficult to ignore for companies trying to bring mycoprotein or precision-fermented ingredients to price-competitive retail markets.
The report does not, however, present engagement as straightforward. Foreign companies must weigh intellectual property protection, tariff exposure, and geopolitical risk. As Dr. van der Kley frames it, the relevant question for many firms is not whether partnership with Chinese manufacturers is risk-free, but whether the risks of engaging outweigh the risks of remaining outside a market that may become the industry's primary manufacturing centre.
The GFI APAC report stops short of predicting outcomes. What it does establish is that the structural conditions, spare capacity, policy support, falling input costs, and competitive pressure, are now aligned in a way that makes a significant Chinese role in global mycoprotein and alternative protein production increasingly plausible. Whether international companies treat that as an opportunity or a threat may depend as much on geopolitics as on fermentation science.
